Recursion Pharmaceuticals: director Robert Hershberg sold 25,000 shares

What happened

• Robert Hershberg, director, exercised options for 25,000 shares at $2.22 per share on Oct 6, 2026, paying $55,500, and the filing reports an open-market sale of 25,000 shares at $5.00 per share on Oct 6, 2026, for $125,000. The filing also lists a derivative disposition of 25,000 shares at $2.22 for $55,500.

Key details

• Transaction dates and prices:
  • Oct 6, 2026 — exercise/conversion (M): 25,000 shares acquired at $2.22, $55,500.
  • Oct 6, 2026 — open market sale (S): 25,000 shares disposed at $5.00, $125,000.
  • Oct 6, 2026 — exercise/conversion (M) derivative disposed: 25,000 shares at $2.22, $55,500.
• Shares owned after the transaction: not reported in this Form 4.
• Footnotes:
  • F1: Transaction pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on Dec 17, 2025.
  • F2: Vesting schedule: one forty-eighth (1/48th) of the shares subject to the award vests one month after Mar 16, 2020 and one forty-eighth (1/48th) vests each month thereafter; date exercisable varies by tranche.
• Filing date and timeliness: Form 4 filed on Oct 7, 2026; the filing covers transactions on Oct 6, 2026 and does not indicate it was filed late.

Why it may matter

• The filing shows exercised options and a contemporaneous open-market sale of the same number of shares on Oct 6, 2026, indicating the shares were sold at once after exercise.
• The transactions are reported as an option exercise (M) and an open-market sale (S); the derivative disposition is reported separately.
• A filing does not show why the insider traded or why the company acted.